Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 17;12(2):154.
doi: 10.3390/pathogens12020154.

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

Dvir Gatt  1 , Isaac Martin  1 , Rawan AlFouzan  1 , Theo J Moraes  1   2
Affiliations
Review

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

Dvir Gatt et al. Pathogens. .

Abstract

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease, especially in young children. Despite its global impact on healthcare, related to its high prevalence and its association with significant morbidity, the current therapy is still mostly supportive. Moreover, while more than 50 years have passed since the first trial of an RSV vaccine (which unfortunately caused enhanced RSV disease), no vaccine has been approved for RSV prevention. In the last two decades, our understanding of the pathogenesis and immunopathology of RSV have continued to evolve, leading to significant advancements in RSV prevention strategies. These include both the development of new potential vaccines and the successful implementation of passive immunization, which, together, will provide coverage from infancy to old age. In this review, we provide an update of the current treatment options for acute disease (RSV-specific and -non-specific) and different therapeutic approaches focusing on RSV prevention.

Keywords: antiviral; bronchiolitis; monoclonal antibodies; respiratory syncytial virus; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Immunization Strategies for RSV [98,99,100,101,102,103,104,106,107,108,109,110,116,123,124,125,126].
See this image and copyright information in PMC

References

    1. Meissner H.C., Rennels M.B., Pickering L.K., Hall C.B. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab. Pediatr. Infect. Dis. J. 2004;23:284–285. doi: 10.1097/01.inf.0000121203.33560.f9. - DOI - PubMed
    1. Suh M., Movva N., Jiang X., Reichert H., Bylsma L.C., Fryzek J.P., Nelson C.B. Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011–2019. J. Infect. Dis. 2022;226:S184–S194. doi: 10.1093/infdis/jiac155. - DOI - PMC - PubMed
    1. Pisesky A., Benchimol E.I., Wong C.A., Hui C., Crowe M., Belair M.A., Pojsupap S., Karnauchow T., O’Hearn K., Yasseen A.S., 3rd, et al. Incidence of Hospitalization for Respiratory Syncytial Virus Infection amongst Children in Ontario, Canada: A Population-Based Study Using Validated Health Administrative Data. PLoS ONE. 2016;11:e0150416. doi: 10.1371/journal.pone.0150416. - DOI - PMC - PubMed
    1. Thampi N., Knight B.D., Thavorn K., Webster R.J., Lanctot K., Hawken S., McNally J.D. Health care costs of hospitalization of young children for respiratory syncytial virus infections: A population-based matched cohort study. CMAJ Open. 2021;9:E948–E956. doi: 10.9778/cmajo.20200219. - DOI - PMC - PubMed
    1. Li Y., Wang X., Blau D.M., Caballero M.T., Feikin D.R., Gill C.J., Madhi S.A., Omer S.B., Simoes E.A.F., Campbell H., et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. Lancet. 2022;399:2047–2064. doi: 10.1016/S0140-6736(22)00478-0. - DOI - PMC - PubMed

LinkOut - more resources